ClaroNav Continues the Expansion of the Dental Navigation System with the U.S. FDA Approval Improving the Dental Imaging Market
ClaroNav’s dental imaging system, Navident EVO is designed to enable dentists to perform endodontic surgeries, dental operations, procedures, or the placement of implants. The navigation system allows dentists to preserve the tooth structures of patients during root canals. This medical device also saves time in performing root canal procedures at the time of locating and accessing canals and enhances the performance efficiency in endodontic surgeries. The Navident EVO system was commercially launched in March 2024 and the company got approval by the U.S. Food and Drug Administration to conduct multiple dental surgeries under the guidance.
“According to Precedence Research’s Report, the global dental imaging market size was USD 4.38 billion in 2023 and is predicted to grow around USD 10.75 billion by 2033, with a remarkable growth to USD 4.79 billion in 2024 expanding at a CAGR of 9.4% from 2024 to 2033.’’
According to the Centers for Disease Control and Prevention (CDC), over 47% of adults aged 30 years and older have some form of periodontal disease, increasing the demand for advanced dental imaging solutions. Additionally, the American Dental Association reported that over 3.5 million people undergo dental procedures like root canals, implants, and crowns annually, further driving the need for precise imaging technologies. In 2022, over 150 million dental X-ray procedures were conducted in the United States alone, according to the National Center for Health Statistics, highlighting the growing reliance on imaging technologies for routine check-ups and complex treatments.
The insertion of artificial intelligence tools in medical devices helps clinicians to perform well by a suitable detection and diagnosis of the dental problems which enables them to plan the treatments accordingly. AI-powered dental imaging systems are developed by multiple companies which assist in the early detection of defects in the body for their early removal resulting in the reduction of health risks. In February 2024, the Israel company, Magentiq Eye reported its clinical trial data which states that the company’s AI-powered colonoscopy tool named Magentiq-Colo CADe is effective in the detection of adenoma by 7% and its removal can be done to reduce the risks associated with colorectal cancer.
“A recent report from Precedence Research Reveals that in the U.S. the dental imaging market size is calculated at USD 1.02 billion in 2023 and is projected to hit around 2.65 billion by 2033, estimated to grow at a CAGR of 10.1% from 2024 to 2033.”
The Envista Company Revenues Based on Regions in 2023
| Name of the Region | Specialty Products and Technologies | Equipment and Consumables |
| North America | $ 702.0 | $ 610.5 |
| Western Europe | $ 447.7 | $ 121.7 |
| Other developed markets | $ 90.4 | $ 36.9 |
| Emerging markets | $ 402.3 | $ 155.0 |
Meet Kesiya, an emerging voice in the ever-evolving dental industry. With over five years of research expertise and a robust microbiology background, Kesiya’s unique insights into healthcare have reshaped how we perceive oral health advancements. But it’s her ability to decode complex scientific findings and transform them into compelling stories that sets her apart.
Her writing isn’t just a presentation of facts; it’s an invitation to dive deeper into the intricate world of dental research and technology. From cutting-edge dental innovations to patient care strategies, Kesiya covers it all with an eye for detail. She brings to life the often-overlooked connections between microbiology and dental health, making her content not only informative but also enlightening.
